Controversial but reportable (marginal benefit)-Ramucirumab

ONLINE FIRST: FDA Grants Priority Review of Ramucirumab for Gastric Cancer, Phase III REGARD Findings Now Online in Lancet; Concerns, Though, from a Lead Recruiter to the Trial(from Oncology Times)
what we know about the drug
"

Ramucirumab

From Wikipedia, the free encyclopedia

Jump to: navigation, search

Ramucirumab ^?

Monoclonal antibody
Type	Whole antibody
Source	Human
Target	VEGFR2 (KDR)
Clinical data
Pregnancy cat.	?
Legal status	Investigational
Identifiers
CAS number	947687-13-0
ATC code	None
UNII	D99YVK4L0X
Chemical data
Formula	C6374H9864N1692O1996S46
Mol. mass	143.6 kDa
(what is this?)  (verify)

Ramucirumab (IMC-1121B)^[1] is a fully human monoclonal antibody (IgG1) being developed for the treatment of solid tumors. It is directed against the vascular endothelial growth factor receptor 2 (VEGFR2). By binding to VEGFR2 it works as a receptor antagonist blocking the binding of vascular endothelial growth factor (VEGF) to VEGFR2. VEGFR2 is known to mediate the majority of the downstream effects of VEGF in angiogenesis.
Ramucirumab is being tested in several phase III clinical trials for the treatment of metastatic gastric adenocarcinoma,^[2] non-small cell lung cancer,^[3] among other types of cancer. On September 26, 2013 Eli Lilly announced that its Phase III study for ramucirumab failed to hit its primary endpoint on progression-free survival among women with metastatic breast cancer.^[4][5]
This drug was developed by ImClone Systems Inc. It was isolated from a native phage display library from Dyax. " wikipedia